Amgen Suit Seeks Halt to Colorado Board’s Drug Price Limits (1)

Drugmaker Amgen Inc. is the first company seeking to challenge state drug pricing boards’ ability to set limits on what health plans pay for prescriptions with a lawsuit against a Colorado vote to pursue a cap for the company’s arthritis drug Enbrel.

The lawsuit from Amgen asks the US District Court for the District of Colorado to enjoin the Colorado Prescription Drug Affordability Board from enforcing a state law that “delegates sweeping authority” to the five-member panel to “impose arbitrary price controls on the sale of prescription drugs, including drugs protected by the federal patent laws.” The board voted Feb. ...